Approved IL-23p19 subunit inhibitors, including guselkumab, typically require intravenous induction dosing in patients with ulcerative colitis. However, the effectiveness and safety of subcutaneous induction remain uncertain due to limited evidence. To address this gap, a study evaluated subcutaneous guselkumab induction in 651 adults with moderately to severely active ulcerative colitis.
The study found that a significantly higher proportion of patients receiving guselkumab achieved clinical remission at week 12 (77 [28%] of 279 vs 9 [6%] of 139; adjusted difference 21%), with sustained benefits at week 24 (49 [35%] and 51 [36%] vs 13 [9%] in placebo). Adverse events were similar across groups (53–61% vs 65%), with no treatment-related deaths or new safety concerns. These findings suggest that guselkumab administered subcutaneously is a safe and effective induction and maintenance…
